Purple Biotech Jumps After New U.S. Patent Allowance for CAPTN-3 Platform

By: Quiver PriceTracker

Posted: 4 hours ago / Sept. 2, 2026 2:47 p.m. UTC

PPBT

Purple Biotech (PPBT) is up 39.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely catalyst is Purple Biotech’s September 2, 2026 announcement that the U.S. Patent and Trademark Office issued a Notice of Allowance tied to its CAPTN-3 multispecific antibody platform. For a small clinical-stage biotech, fresh intellectual property protection can boost optimism around future partnering potential and the long-term value of its lead programs.

Details:

The company disclosed in a Form 6-K that a newly allowed U.S. patent application covers tri-specific antibody constructs and methods of use tied to CAPTN-3.

Management described the allowance as strengthening protection for the platform’s modular architecture, which is designed to support multiple antibody candidates across cancer targets.

The filing also said the allowed claims expand the platform’s versatility and future development and partnering potential, which likely helped sentiment.

Recent company materials showed IM1240 as the lead CAPTN-3 candidate, with management targeting entry into clinical studies in 2027 and stating that cash as of June 30, 2026 was expected to fund operations through mid-2027.

Sources:

SEC, Purple Biotech, Benzinga

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$PPBT Hedge Fund Activity

We have seen 8 institutional investors add shares of $PPBT stock to their portfolio, and 15 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

TWO SIGMA INVESTMENTS, LP removed 155,353 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $627,626
SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 40,556 shares (-75.9%) from their portfolio in Q2 2026, for an estimated $68,134
HRT FINANCIAL LP added 14,640 shares (+inf%) to their portfolio in Q2 2026, for an estimated $24,595
INDEPENDENT ADVISOR ALLIANCE added 11,901 shares (+inf%) to their portfolio in Q2 2026, for an estimated $19,993
SMARTHARVEST PORTFOLIOS, LLC added 10,341 shares (+57.0%) to their portfolio in Q2 2026, for an estimated $17,372
CITADEL ADVISORS LLC removed 4,274 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $17,266
BNP PARIBAS FINANCIAL MARKETS removed 1,957 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $3,287

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.